Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice.

Clin Genitourin Cancer 2018 04 25;16(2):e297-e305. Epub 2017 Sep 25.

Department of Pharmacy, University Hospital, Besançon, France; University Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions hôte-greffon-tumeur, Ingénierie Cellulaire et Génique, Besançon, France. Electronic address:

Purpose: To describe factors associated with overall survival (OS) among patients with metastatic clear-cell renal-cell carcinoma (mccRCC) in regard to evolution of systemic therapies.

Patients And Methods: Two hundred twenty-four consecutive patients with histologically confirmed mccRCC who received targeted therapy on first-line treatment between January 2007 and March 2015 were included. The primary end point was OS for metastatic first-line or second-line treatment. An analysis of prognostic factors of long survival was performed using a 2-step approach: univariate, then multivariate analysis.

Results: Median OS [95% confidence interval] was 19.4 months [16.1-24.9]. Three prognostic factors were identified in first-line treatment: Memorial Sloan Kettering Cancer Center (MSKCC) favorable and intermediate risks (hazard ratio [95% confidence interval] = 0.362 [0.207-0.630] and 0.561 [0.393-0.801], respectively, P = 4.10), metastasectomy (0.667 [0.468-0.951], P = .03), and lack of lymph node metastasis (0.715 [0.513-0.994], P = .049). In second-line treatment, median OS [95% confidence interval] was 11.0 months [8.9-14.4] for 167 patients. Three different prognostic factors predicted long survival: toxicity for first-line treatment discontinuation (HR [95% confidence interval] = 0.298 [0.180-0.493], P < 10), duration of disease control in first-line therapy (0.961 [0.942-0.979], P = 2.10), and MSKCC favorable and intermediate risks (0.461 [0.252-0.843] and 0.936 [0.607-1.443], respectively, P = .02).

Conclusion: These real-life data confirm the positive impact of targeted therapy in the mccRCC setting. Moreover, it emphasizes the importance of considering many factors in order to better estimate prognosis in patient pretreated with systemic therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.09.006DOI Listing
April 2018
Save 15% Survey

Similar Publications

Immunosuppression as a risk factor for COVID-19: a meta-analysis.

Intern Med J 2021 Feb;51(2):199-205

Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia.

Background: While immunosuppression poses a theoretical increase in the risk of COVID-19, the nature of this relationship is yet to be ascertained.

Aims: To determine whether immunosuppressed patients are at higher risk of COVID-19 to help inform the management of patients receiving immunosuppressant therapies during the pandemic.

Methods: We performed a random-effects meta-analysis of data from studies that reported on the prevalence of immunosuppression among patient cohorts with COVID-19. Read More

View Article and Full-Text PDF
February 2021

Incidence and predictors of idiopathic pulmonary fibrosis complicating Type 2 diabetes: the Fremantle Diabetes Study Phase I.

Intern Med J 2021 Feb;51(2):276-279

Medical School, The University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia.

During 106 865 person-years of follow up, 17 (1.3%) Fremantle Diabetes Study Phase I participants with Type 2 diabetes and 57 (1.1%) matched individuals without diabetes developed idiopathic pulmonary fibrosis (IPF), an incidence rate ratio (95% confidence interval) of 1. Read More

View Article and Full-Text PDF
February 2021

Belimumab for systemic lupus erythematosus.

Cochrane Database Syst Rev 2021 Feb 25;2:CD010668. Epub 2021 Feb 25.

Department of Medicine - Rheumatology, University of Alabama at Birmingham, Birmingham, USA.

Background: Belimumab, the first biologic approved for the treatment of systemic lupus erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE and help control disease activity.

Objectives: To assess the benefits and harms of belimumab (alone or in combination) in systematic lupus erythematosus.

Search Methods: An Information Specialist carried out the searches of CENTRAL, MEDLINE, Embase, CINAHL, Web of Science, the World Health Organization (WHO) International Clinical Trials Registry Platform, and clinicaltrials. Read More

View Article and Full-Text PDF
February 2021

Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study.

J Obstet Gynaecol Res 2021 Feb 25. Epub 2021 Feb 25.

Department of Pharmacy, Toranomon Hospital, Minato-ku, Tokyo, Japan.

Aim: To assess the teratogenic risk of domperidone by comparing the incidence of major malformation with domperidone to a control.

Methods: Pregnancy outcome data were obtained for women at two Japanese facilities that provide counseling on drug use during pregnancy between April 1988 and December 2017. The incidence of major malformation was calculated among infants born to women taking domperidone (n = 519), nonteratogenic drugs (control, n = 1673), or metoclopramide (reference, n = 241) during the first trimester of pregnancy. Read More

View Article and Full-Text PDF
February 2021

Systemic Air Embolism Complicating Computed Tomography-guided Percutaneous Transthoracic Biopsy of Cavitary Lung Lesions: A Systematic Review.

J Thorac Imaging 2021 Feb 25. Epub 2021 Feb 25.

Department of Radiology, Vancouver General Hospital Department of Radiology, University of British Columbia, Vancouver, BC, Canada.

Purpose: Cavitary lung lesions often pose a diagnostic challenge, and tissue sampling can be required to obtain a confident diagnosis. Many authors contend that a computed tomography-guided percutaneous transthoracic lung biopsy (PTLB) of a cavitary lung lesion places a patient at higher risk for systemic air embolism (SAE) compared with biopsy of a noncavitary lesion.

Materials And Methods: We reviewed the literature for studies of SAE complicating PTLB. Read More

View Article and Full-Text PDF
February 2021